Project description
Novel peptide-based antibiotics against drug-resistant bacteria
Israel-based Omnix Medical is developing novel antibiotic agents for the treatment of infections caused by drug-resistant bacteria. The company’s proprietary platform technology is changing the biodegradability of antimicrobial peptides, creating a new class of antibiotics with a unique mechanism of action, which is effective regardless of underlying resistance patterns. The goal of the EU-funded OMN6 project is to demonstrate clinical safety and efficacy in the treatment of deadly nosocomial Acinetobacter baumannii infections. To that end, it will support Omnix Medical in the commercialisation of its lead antibiotic candidate, which has already made it past the proof-of-concept stage.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinemedicinal chemistry
- natural sciencesbiological sciencesbiochemistrybiomolecules
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programme(s)
Funding Scheme
SME-2b - SME Instrument (grant only and blended finance)Coordinator
OMNIX MEDICAL LTD
Net EU contribution
€ 2 389 674,70
Address
Racah 1
9270401 Jerusalem
Israel
9270401 Jerusalem
Israel
See on map
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 1 024 146,30